DALLAS, July 28, 2015 /PRNewswire/ --
According to a new market research report "European Injectable Drug Delivery Market By Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) - Forecast to 2020", published by MarketsandMarkets, the European Injectable Drug Delivery Market is expected to reach $207.3 Billion by 2020 from $114.7 Billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020.
Browse 230 market data Tables and 43 Figures spread through 247 Pages and in-depth TOC on "European Injectable Drug Delivery Market"
Early buyers will receive 10% customization on this report.
Injectable drug delivery offers a promising alternative for the delivery of drugs that are ineffective when administered orally. Injectable drug delivery is aimed to maximize patient compliance and reduce the frequency of dosage administration without compromising the effectiveness of the treatment.
Ask for PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=1205
The report segments the European Injectable Drug Delivery Market on the basis of types, therapeutic applications, usage patterns, modes of administration, end users, and regions. On the basis of type, the formulations segment is expected to account for the largest share in 2015, closely followed by the devices segment. The formulations segment is expected to grow at the highest CAGR during the forecast period, owing to the rising prevalence of chronic diseases, increase in demand of self-injection devices, growth of the biologics market, technological advancements, emphasis on innovation of formulations, and benefits such high efficacy and reduced side effects offered by formulations. The formulations market is further segmented into conventional drug delivery formulations, novel drug delivery formulations, and long-acting injection formulations. The devices market is further segmented into conventional injection devices, self-injections, and other devices.
On the basis of therapeutic application, the European Injectable Drug Delivery Market is segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. On the basis of usage pattern, the market is segmented into curative care, immunization, and others.
On the basis of mode of administration, the European Injectable Drug Delivery Market is segmented into skin, organs, central nervous system, and circulatory/musculoskeletal system. On the basis of end user, the market is segmented into hospitals/clinics, home care settings, research laboratories, pharma and biotech companies, and other end users.
Geographically, the market is dominated by Germany, followed by France. Germany is expected to account for the largest share of the European Injectable Drug Delivery Market in 2015, with the highest growth rate during the forecast period.
Key players in the European Injectable Drug Delivery Market include Becton, Dickinson and Company (U.S.), Baxter International Inc. (U.S.), Gerresheimer AG (Germany), Pfizer Inc. (U.S.), Schott AG (Germany), Sandoz,(Germany) Teva Pharmaceutical Industries Ltd. (Israel), and Eli Lilly and Company (U.S.).
Browse Related Reports:
Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017
Top 10 Drug Delivery Technologies Market (Topical, Oral Time Release/Sustained Release, Targeted Delivery, Encapsulation, Aerosol/Inhalation, Transdermal, Implants, Injectable, Liposomal, Pegylation) - Global Trends, Challenges & Forecasts up till 2015
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets